WY P&T Committee Meeting Minutes
Thursday, August 11, 2022
Cheyenne, WY and via Zoom
10 a.m. – 1 p.m.

Members present: Paul Bongat, Melinda Carroll, Hoo Feng Choo, Evan Crump, Scott Johnston, Kristen Lovas, Chris Mosier, Garry Needham, Danae Stampfli, Patrick Yost

Ex-officio: Cori Cooper, Melissa Hunter, James Bush

Excused: Paul Johnson

Guests: Melissa Eames, Sandra Deaver, Patrick Johnson, Matt Robison (CHC), Corwyn Moss (CHC), Melissa Mele (CHC), Nikki Yost (CHC), Kailee Becking (UW Student), Steve Angelcyk (Embecta), Kimberly Raymer (NovoNordisk), Chris Santarone (BMS), Gary Parenteau (Dexcom), John Flatt (Marinus), Michele Puyear (Genentech), Jane Stephen (Amgen), David Large (Biohaven), KayOnda Bayo (BMS), Lori Howarth (Bayer), Phil Wetttestad (Novartis), Susan Kelly (Spark), Gina Heinen (NovoNordisk), Bill Gittenger (Mitsubishi Tanabe), Deb Guay (Gene), Joe Payne (Horizon Therapeutics), Ben Zoller (UW Student)

Mr. Mosier called the meeting to order at 10:00 a.m.

Introductions were made.

Approval of Minutes
The minutes of the May 12, 2022 meeting were approved.

Department of Health
A. Pharmacy Program Manager Report: The search continues for Teri Green’s replacement as State Medicaid Agent. Jan Stall is interim and Head of Provider Services. Discussions have started to refine requirements for the PBMS RFP. The Change Healthcare contract expires in 2024. The DUR contract ends on June 30, 2023. Cori is also working on drafting the RFP, which will be released in November.

B. Medical Director Report: Nothing to report.

C. DUR Manager Report: Alissa has resigned from the Committee. We will need to find a PA or NP to fill her position.

Old Business:
There was no old business to discuss.

New Business
A. PA Criteria

1. Review existing criteria
i. There was no criteria to discuss.

2. New Drugs
   i. Tlando is indicated for treatment of testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchietomy, Klinefelter syndrome, chemotherapy or toxic damage from alcohol or heavy metals; gonadotropin or luteinizing hormone-releasing hormone deficiency; or pituitary-hypothalamic injury from tumors, trauma or radiation. The Committee agreed there was no evidence of a difference in safety or efficacy. There was a motion, second and all were in favor of limiting to indication and Tlando was referred to the Department of Health for cost analysis.
   
   ii. Quviviq is indicated for treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in adults. The Committee agreed there was no evidence of a difference in safety or efficacy. It will be referred to the Department of Health for cost analysis.
   
   iii. Vtamo is indicated for treatment of plaque psoriasis in adults. The Committee agreed there was no evidence of a difference in safety or efficacy. There was a motion, second and all were in favor of limiting to indication and Vtamo will be referred to the Department of Health for cost analysis.
   
   iv. Camzyos is indicated for treatment of symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II to III) in adults to improve functional capacity and symptoms. KayOnda Bayo (BMS) provided public comment. Current options, including beta blockers, calcium channel blockers and disopyramide, address symptoms only. The majority of patients in the Camzyos studies were on beta blockers and calcium channel blockers. Camzyos is the only medication on the market that addresses the underlying mechanism of disease. There are additional ongoing studies with larger numbers of patients. It is also being explored for other indications. There are a variety of drug interactions associated with the Cytochrome P450 system. Grapefruit juice is the only food interaction that is currently listed. Cardiac echoes should be monitored every 4 weeks for the first 3 months during the initiation phase. During the maintenance phase, echoes are monitored every 12 weeks. Every time the dosage is changed, echoes should be performed at 4 weeks.
   There was a motion, second and all were in favor of limiting to indication.
   
   v. Mounjaro is approved to improve glycemic control in adults with type 2 diabetes mellitus. No outcomes data are available at this time. The Committee agreed there was no evidence of a difference in safety or efficacy. It will be referred to the Department of Health for cost analysis.
   
   vi. Lyvispah is indicated for treatment of spasticity resulting from multiple sclerosis particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Lyvispah will require prior authorization.
   
   vii. Voquezna is indicated for treatment of *H. pylori* infection in adults. Current guidelines call for bismuth triple therapy as first line. Voquezna will be limited to indication and referred to the Department of Health for cost analysis.
   
   viii. Ztalmy is indicated for treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients 2 years and older. This is a rare disorder that is refractory to medication therapy. There is a Phase 3
study currently in progress for tubular sclerosis, and an IV form being studied for status epilepticus. There was a motion to limit to indication. The motion was seconded and all were in favor.

3. Determine need for criteria
   i. None

4. Physician Administered Drugs
   i. Radicava is indicated for the treatment of amyotrophic lateral sclerosis. There was a motion, second and all were in favor of limiting to indication.

Other
The Paxlovid prior authorization criteria was discussed. Pharmacies are not submitting a PA because it is too much work. Medicaid only pays for the dispensing fee. The previous discussion was based on some concern about use in prevention. Based on the time sensitivity of the treatment, the prior authorization may be an unnecessary burden. There was a motion, second and all were in favor of removing the prior authorization requirements.

There being no further business, the open portion of the meeting adjourned at 10:40 am and the Committee met in closed session. During the closed session, the annual planning meeting was held.

Respectfully Submitted,

Aimee Lewis
WYDUR Manager